AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03783390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Youth randomized to the active condition will participate in an organized exercise program. During the exercise program, adolescents will participate in a supervised structured exercise (treadmill walking/cycling on stationary bike) on 3 days equivalent to approximately 180 min/week of moderate-intensity exercise. The rationale for this dose of structured exercise is based on national (ADA) and international physical activity recommendations for youth of 60 minutes/day.
Study NCT03783390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newsletter
Description: Families will receive a monthly newsletter with parenting tips, sample praise statements, and child-appropriate activities and recipes identical to what has been used in the work of leaders in the field of pediatric obesity. Previous research suggests that newsletter/mail interventions are well received by participants and are frequently included in federally funded health intervention studies.
Study NCT03127371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
Study NCT03127371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
Study NCT02461992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusions of Xyntha
Description: A single dose 50IU/kg dose of Xyntha administered by intravenous infusion within 10 minutes on Day 1
Study NCT00724997 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GHB01L1
Description: Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer
Study NCT00362089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Marinol D-40
Description: Marinol D-40, three capsules per day, from 15th week of gestation until 4th month of lactation
Study NCT03988335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIST4721
Description: RIST4721 oral solution
Study NCT03988335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution
Study NCT00978029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual tablet, once daily
Study NCT00978029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 39641
Description: Allergy immunotherapy tablet (sublingual)
Study NCT00902785 — intervention group
Intervention type: OTHER
Intervention: no drug
Description: observational no drug
Study NCT02933697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Patients will be instructed to take one tablet of 2.5 mg twice daily: one tablet in the morning and one in the evening at approximately the same time every day (with about 12 hours gap) irrespective of the time of dialysis.
Study NCT02933697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Description: Subjects in phenprocoumon treatment group will receive phenprocoumon individually adjusted to an INR of 2.0-3.0 as recommended in the appropriate SmPC for AF patients.
Study NCT04411355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: control by dietitian
Study NCT04411355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise programs
Description: In line with the address information of the intervention patients, purpose/content of the study was discussed with the gyms of municipalities and patients were made to benefit from these facilities for free. For the patients preferring private gyms, it was ensured that discounts were made for the patients.
Study NCT04380246 — intervention group
Intervention type: OTHER
Intervention: Qualitative Interview
Description: There is no intervention as part of this study. Clinicians will participate in a qualitative interview.
Study NCT04411355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control by psychiatrist
Description: The psychiatrist assessed the suitability of the patients to the study, assessed the patients having adaptation problems with respect to lifestyle changes in monthly controls and also played roles in teaching the coping methods to patients and applying and interpreting the hospital anxiety and depression scale.
Study NCT01425151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-Gel
Description: Oropharyngeal leak pressure Insertion success
Study NCT01425151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProSeal
Description: Oropharyngeal leak pressure Insertion success
Study NCT03303794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: 1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
Study NCT03303794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% bupivacaine
Description: 0.25% bupivacaine in patients undergoing total knee arthroplasty
Study NCT03303794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Description: 0.25% bupivacaine in patients undergoing total knee arthroplasty
Study NCT02965807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchial Thermoplasty
Description: patients will be under Bronchial Thermoplasty approximately every three weeks.And totally having three surgerys will be considered as completed.
Study NCT02970292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg, 20 mg, or 10 mg , taken as two tablets once daily by mouth
Study NCT02970292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken as two tablets, once daily by mouth
Study NCT00832559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVA21
Description: 1, 3 or 6 doses of CAVATAK (10\^9 TCID50) at 48 hour intervals.
Study NCT01797575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her antidepressant and/or mood stabilizer medicine
Study NCT01797575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl-cysteine (NAC)
Description: taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her antidepressant and/or mood stabilizer medicine
Study NCT01797575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: research subject will be taking placebo in addition to his/her antidepressant and/or mood stabilizer medicine
Study NCT04041284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Monthly 225 mg subcutaneous
Study NCT04041284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT04096196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe City game
Description: The game intervention uses a game-based learning approach to teach players how to recognize and remove injury hazards from different homes and sports areas. It also highlights the need to pay attention to traffic and safety facilities to prevent injuries in a real-world environment. Players will create their own avatar to assume the duties of safety inspectors in the game. Point, level and reward systems will be included to increase player motivation to engage in the game.
Study NCT04096196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
Study NCT00757250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7
Description: Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day
Study NCT01478035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
Study NCT01478035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 18 mg /Kg/day iv as loading dose. 24 hours later placebo 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
Study NCT01437774 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thrombectomy (ReStore or Merci)
Description: Each arm will use either ReStore or Merci as the primary thrombectomy device
Study NCT01437774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thrombectomy (ReStore or Merci)
Description: Each arm will use either ReStore or Merci as the primary thrombectomy device
Study NCT03809611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UNR844-Cl
Description: 1.5% Ophthalmic solution for topical ocular administration
Study NCT03809611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02803021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - SR15-47-Z13-076)
Study NCT00713427 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: WallFlex™ Biliary Partially-Covered Stent
Description: Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is partially covered with a polymer to reduce the potential for tumor ingrowth through the stent.
Study NCT03730155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCT intervention.
Description: 8-week course with 2 hours sessions weekly. Participants should meditate 25 min. pr. day during the 8 weeks.
Study NCT01232829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given PO
Study NCT06258070 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Abobotulinumtoxin A injection for bruxism
Description: Trigger points were detected with careful palpating of the masticatory muscles (masseter and temporalis muscles) of patients suffering from bruxism. Each trigger point received 0,05 lm ol reconstituted solution of Abobotulinumtoxin A. Dysport (Ipsen Pharma, Germany) was reconstituted with 0.9% sodium chloride solution so that 0.1 ml corresponded to 25 U.
Study NCT02223260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran
Description: Experimental dose chosen based on age and weight
Study NCT00236977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer
Description: iron sucrose injection; 500 mg intravenous (IV) infusion administered over 3.5-4 hours on Days 0 and 14, or 200 mg injections administered over 2-5 minutes on 5 different occasions from Day 0 to Day 14.
Study NCT00236977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: oral iron tablets; 325 mg three times a day orally for 56 days
Study NCT00749996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIAM™ Spinal Stabilization System
Description: The DIAM™ Spinal Stabilization System is a spacer that is inserted between adjoining spinous processes after doing a standard herniectomy procedure using a posterior surgical approach.
Study NCT00749996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Herniectomy
Description: Herniectomy is defined as the removal of the extruded/protruded/sequestrated disc material. This is done by probing the annulus and disc space and removing all mobile disc fragments.
Study NCT03711500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
Study NCT03711500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
Study NCT01801956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: free membership of a sport club
Study NCT01801956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interview
Description: Four motivational interviews by instructors of the local sport club
Study NCT01801956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: Four motivational interviews by instructors of the local sport club
Study NCT01801956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual arena
Description: Uploading of training data from a GPS-watch to a virtual arena
Study NCT04015895 — intervention group
Intervention type: OTHER
Intervention: DEFCO tool
Description: The Detection of social frailties and coordination of the path of patients in cancer: a new approach by an expert computer system DEFCO tool is questionnaire to identify their social vulnerabilities. A neural network instantly identifies the patient's fragility and sends the result by email to the professionals identified in the organization of each center. These professionals then relay to the social workers in order to take care of the patient's fragility.
Study NCT04505241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely-delivered physical activity promotion
Description: Over video-call, participants will receive educational content on safely increasing their levels of physical activity (e.g., selecting an appropriate form of exercise, minimizing health risks, the importance of planning), will receive daily text messages (see arm descriptions) for six weeks and complete a 10-15 minute check-in call at the 3-week point of the intervention to assess compliance with daily step goals as well as to help problem-solve barriers to compliance.
Study NCT04138485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro10
Description: 10% liquid formulation of human immunoglobulin for IVIG
Study NCT04138485 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5% human albumin solution stabilized with 250 mmol/L L-proline
Study NCT04933929 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Post-hospitalization nutritional monitoring
Description: Post-hospitalization nutritional monitoring, carried out by dieticians from Saveurs \& Vie. Consultations are done remotely, by phone only. Dietitians have gained experience in home nutritional monitoring of elderly people over the phone during the first wave of Coronavirus disease 2019 (COVID-19) .
Study NCT04933929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-hospitalization nutritional monitoring
Description: Post-hospitalization nutritional monitoring, carried out by dieticians from Saveurs \& Vie. Consultations are done remotely, by phone only. Dietitians have gained experience in home nutritional monitoring of elderly people over the phone during the first wave of Coronavirus disease 2019 (COVID-19) .
Study NCT00264706 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nona-L-arginine
Study NCT00586209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Glutamine
Description: L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (>66.7 kg)
Study NCT00586209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine
Study NCT00578682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-557
Description: Single IV dose of 3 mg/kg
Study NCT00578682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-557
Description: Single IV dose of 15 mg/kg
Study NCT00578682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-557
Description: Single IV dose of 30 mg/kg
Study NCT00578682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-557
Description: Single IV dose of 0.3 mg/kg
Study NCT01732809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AbobotulinumtoxinA (ABO)
Description: Isovolumetric (0.02 mL) doses of 2 units of abobotulinumtoxinA injected on one side of the forehead.
Study NCT01732809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA (ONA)
Description: Isovolumetric (0.02 mL) doses of 2 units of onabotulinumtoxinA injected on the other side of the forehead.
Study NCT04609852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E8001
Description: Intravenous infusion.
Study NCT04609852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion.
Study NCT03106623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-8577
Description: Oral administration of ONO-8577 once a daily for 4 weeks
Study NCT03106623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin succinate + mirabegron
Description: Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
Study NCT03106623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of Placebo once a daily for 4 weeks
Study NCT05058833 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.
Study NCT05058833 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary flow reserve and index of microcirculatory dysfunction
Description: Coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).
Study NCT02071407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: For patients allocated into group N2, 2 mg midazolam will be injected intravenously, and then it will be given at 0.05-0.1 mg/(kg·h) by intravenous infusion. If a surgery is needed, infusion of midazolam will begin 3 hours after the operation and continue for at least 72 hours. During the sedation with midazolam, BIS should be kept at 60 to 80.~Morphine can be used to supply adequate analgesia.
Study NCT02071407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02370615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272
Description: TAK-272 tablet.
Study NCT02370615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin tablet.
Study NCT02370615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole oral solution
Study NCT02370615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup.
Study NCT00835237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: Intramuscular, single dose.
Study NCT00835237 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Decavac™
Description: Intramuscular, single dose.
Study NCT04467307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigit bronchoscopy
Description: After general anesthesia, the airway is checked with a rigid bronchoscope suitable for the age. If there is a foreign body, it is removed by forceps.
Study NCT03339921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections for chronic compartment syndrome
Description: Botulinum toxin will be injected in the upper and lower portion of the affected area with a syringe